Recently, in a randomized clinical study in T2D patients at high risk for progressive kidney disease, baricitinib, an oral, reversible selective inhibitor of JAK1 and JAK2 reduced albuminuria [41]. Here, JAK2 is linked to type 2 diabetes mellitus.